These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 55599)

  • 1. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.
    Marsden CD; Parkes JD
    Lancet; 1976 Feb; 1(7954):292-6. PubMed ID: 55599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.
    Schuh LA; Bennett JP
    Neurology; 1993 Aug; 43(8):1545-50. PubMed ID: 8351009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease.
    Pourcher E; Bonnet AM; Kefalos J; Dubois B; Agid Y
    Mov Disord; 1989; 4(3):195-201. PubMed ID: 2779590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variations in the "on-off" effect.
    Yahr MD
    Adv Neurol; 1974; 5():397-9. PubMed ID: 4440587
    [No Abstract]   [Full Text] [Related]  

  • 5. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
    Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter: Diphasic dyskinesia during levodopa therapy.
    Barbeau A
    Lancet; 1975 Mar; 1(7909):756. PubMed ID: 47527
    [No Abstract]   [Full Text] [Related]  

  • 7. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease.
    Arabia G; Zappia M; Bosco D; Crescibene L; Bagalà A; Bastone L; Caracciolo M; Scornaienghi M; Quattrone A
    Neurol Sci; 2002 Sep; 23 Suppl 2():S53-4. PubMed ID: 12548340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early-morning OFF and levodopa dose failures in patients with Parkinson's disease attending a routine clinical appointment using Time-to-ON Questionnaire.
    Stocchi F; Coletti C; Bonassi S; Radicati FG; Vacca L
    Eur J Neurol; 2019 May; 26(5):821-826. PubMed ID: 30585679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deprenyl in Parkinson's disease.
    Lees AJ; Shaw KM; Kohout LJ; Stern GM; Elsworth JD; Sandler M; Youdim MB
    Lancet; 1977 Oct; 2(8042):791-5. PubMed ID: 71602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
    Lander CM; Lees A; Stern G
    Clin Exp Neurol; 1979; 16():197-203. PubMed ID: 121706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease.
    Sweet RD; McDowell FH
    Neurology; 1974 Oct; 24(10):953-6. PubMed ID: 4472237
    [No Abstract]   [Full Text] [Related]  

  • 12. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter: Dyskinesias during levodopa therapy.
    Tolosa ES; Maritn WE; Cohen HP
    Lancet; 1975 Jun; 1(7921):1381-2. PubMed ID: 48968
    [No Abstract]   [Full Text] [Related]  

  • 14. Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations.
    Chase TN; Juncos J; Serrati C; Fabbrini G; Bruno G
    Adv Neurol; 1987; 45():477-80. PubMed ID: 3103391
    [No Abstract]   [Full Text] [Related]  

  • 15. On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy.
    Reilly DK; Hershey L; Rivera-Calimlim L; Shoulson I
    Adv Neurol; 1983; 37():51-60. PubMed ID: 6344591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinsonism and levodopa: a five-year experience.
    Delaney P; Fermaglich J
    J Clin Pharmacol; 1976; 16(11-12):652-9. PubMed ID: 791974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levodopa and the "on-off" effect.
    Caine DB; Claveria LE; Allen JG
    Adv Neurol; 1974; 5():341-4. PubMed ID: 4440583
    [No Abstract]   [Full Text] [Related]  

  • 18. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptoms and side effects in the course of Parkinson's disease.
    Birkmayer W; Danielczyk W; Riederer P
    J Neural Transm Suppl; 1983; 19():185-99. PubMed ID: 6583306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations.
    Sage JI; Mark MH
    Ann Neurol; 1991 Oct; 30(4):616-7. PubMed ID: 1789688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.